Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new?
Expert Opin Drug Metab Toxicol
; 20(5): 307-317, 2024 May.
Article
de En
| MEDLINE
| ID: mdl-38668452
ABSTRACT
INTRODUCTION:
Irritable bowel syndrome (IBS), which presents a significant healthcare and socioeconomic burden, is one of the main issues in the field of therapy. Hence, it is imperative to tackle this matter by evaluating the safety and efficacy of the available treatments and determining the ideal approach for each patient. AREAS COVERED We reviewed the pharmacokinetics and safety of pharmacologic interventions administered in diarrhea-predominant IBS (IBS-D) patients. PubMed, Google Scholar and the USFDA databases were searched up to November 2023 to include all updated information on eluxadoline, alosetron, and rifaximin. EXPERT OPINION The most effective way to treat IBS-D is to focus on managing the most common symptoms. However, healthcare providers face a challenge when it comes to identifying the right treatment for each patient, and the root cause of this is the diversity of IBS-D population. Studies have shown that there are differences in how men and women metabolize drugs, which may lead to gender-specific adverse reactions. Women tend to have higher drug concentrations in their bloodstream and take longer to eliminate them. Therefore, healthcare providers may need to reduce the dosage for female patients. Integrating IBS care into sustainable development efforts can indirectly contribute to achieving SDGs and promote health and well-being for all.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Agents gastro-intestinaux
/
Syndrome du côlon irritable
/
Diarrhée
Limites:
Animals
/
Female
/
Humans
/
Male
Langue:
En
Journal:
Expert Opin Drug Metab Toxicol
Sujet du journal:
METABOLISMO
/
TOXICOLOGIA
Année:
2024
Type de document:
Article
Pays d'affiliation:
Iran
Pays de publication:
Royaume-Uni